QLEARON Receives Notice of Allowance from the U.S. Patent Office for its novel antimicrobial platform

Yokneam-Israel (Jun, 10, 2021) -- QLEARON (Previously N.S.C Nanosono Cooperation LTD), Israeli-based startup which has developed groundbreaking antimicrobial technology against antibiotic-resistance bacteria, announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its proven antimicrobial platform.

The two patents (No. US 10,995,011 / US 10,998,467), titled Composition of Metal Oxide Semiconductor Nanomaterials, and its Hemostatic Polymers, includes methods and approach of using metal oxide nanomaterials as bactericidal and wound healing accelerator.

"This is a major milestone for founding our new novel-approach in the global marketplace. Said Ronen Sarusi, Founder & CEO of QLEARON. “Our evidence-based platform plays a pivotal role in preventing infections and biofilms. Every single year, tens of thousands people die in the US as a consequence of antibiotic-resistant infections. Our technology which can be incorporated in many objects in such highly infectious settings of hospitals and clinics, can be very useful in curbing the growing rate of infections, as well as reducing its enormous annual cost for the health system” he added.

7 Hakidma

About Qlearon
QLEARON's mission is to develop an everlasting biocompatible & biodegradable, antimicrobial submicron composite filter on an industrial scale to improve quality of life and health and reduce the economic impact of infection in the world's healthcare system while protecting the environment.
QLEARON antimicrobial technology has been proven effective against the most clinically relevant, and antibiotic-resistant bacteria, viruses, yeasts and mold with outstanding “total-kill” results.

This release was published on openPR.